Gene Analysis and Biomarker Identification Collaborative Network
Many obstacles lie in the path leading from basic research to clinical biomarker identification and validation. While gene expression microarrays, proteomics tools, imaging techniques, and next-generation sequencing can generate massive amounts of data, differences among tools, platforms, and samples (such as various chip manufacturers, differing patient and normal subject populations, and differences among software platforms used for data collection and analysis) have hampered clinical translation. But new initiatives aimed at standardization are beginning to emerge to meet this need.
The National Cancer Institute (NCI) established and sponsors the cancer Biomedical Informatics Grid (caBIG) as a way for members of the cancer communityincluding researchers, physicians, and patients-to share information. One of the major goals of caBIG is to develop standards and tools for data acquisition, analysis, and dissemination and it is committed to the open source environment when it comes to the development of tools, access to resources, and source code. Currently, the caBIG community includes more than 50 NCI-designated cancer centers, 30 other federal, academic, not-for-profit, and industry groups, numerous NCI-supported research groups, and over 900 individual researchers who have contributed to the development of tools and services already in existence, such as The Cancer Genome Atlas, clinical trial compatibility framework tools [e.g., Cancer Adverse Event Reporting System (caAERS)], life science distribution tools [e.g., Cancer Genome-Wide Association Studies (caGWAS)], and a data sharing and security framework tool. To further improve compatibility among the broad range of tools and software programs being used in cancer research, caBIG now offers a compatibility certification program.
Certification
May Dongmei Wang and her group at the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Institute of Technology recently developed two new software programs that remove noise and artifacts from gene expression microarray data to enable identification of potential cancer biomarkers. Wang submitted those programs, called caCORRECT (chip artifact CORRECTion) and omniBioMarker, to caBIG for certification. "When we went through the review process, caBIG was supportive and impressed because we developed our software in-house, not through their funding," she says.
According to Wang, NCI-funded researchers are now strongly recommended to make sure that their data and tools can interface with the grid to facilitate sharing. Any new software systems must also be compatible and able to communicate. There are two types of compatibility reviews at caBIG-one concerning the syntactic compatibility for the grid, which requires the use of Java programming, and the other is a semantic compatibility, which requires the use of UML (Unified Modeling Language). Wang was funded to develop her caCORRECT and omniBioMarker programs by the National Institutes of Health, the Georgia Cancer Coalition, Microsoft Research, and Hewlett-Packard. For groups like hers to be to be considered for certification, they are required to undergo a thorough review by a caBIG-appointed committee consisting of two known and two anonymous mentors. The review process can often take a year or more.
In the end, Wang's programs were given silver-level certification compatibility, meaning that these tools were judged to be applicable to most currently funded caBIG developer projects. Other levels of caBIG certification include: (i) legacy, applicable to those systems designed without awareness of or prior to the availability of the compatibility guidelines, and which do not meet any requirements for interoperability; (ii) bronze, designed for certification of software products not created as part of the caBIG program but capable of being certified as compliant with caBIG guidelines; and (iii) gold, the highest level, currently being defined for a "formalized grid architecture and data standards that will enable standardized advertising, discovery, and use of all federated caBIG resources." Wang says caBIG certification is important because it indicates that anyone in the cancer research community can use the tools, and the users are assured that the software tools are interoperable.
Curse of Dimensionality
The need for compatibility can extend beyond software. A major issue surrounding the discovery of biomarkers is the volume of data generated by individual laboratories that each look at a small number of genes or proteins within a subset of individuals. Wang notes that this creates a problem in early translational research known as the "curse of dimensionality," the challenge of solving high-dimension problems in mathematical spaces, where the complexity increases exponentially with increasing dimensionfor example, going from a line to a square to a cube. In biologic pattern recognition (e.g., determining the association of biomarkers with a type of cancer or whether the cancer will progress or respond to chemotherapy),
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Features the training set size increases exponentially as more dimensions-that is, features or factors-are needed to classify or identify future samples. According to Wang, when it comes to translational cancer research, biomarker identification for all stages and types of cancer probably includes as many as 28,000 dimensions based on estimated gene number. This means that the usual number of samples or patient numbers available in clinical studies won't be adequate (even before considering the cost of such an analysis), due in part to the fact that human genes are not independent of one another. If genes were independent, Wang believes sample numbers might be manageable. Because of the lack of independence of gene expression, the analysis of microarray samples with feature selection algorithms is also subject to the curse of dimensionality. One approach to dealing with the dimension problem in cancer biomarker identification is to use clinically identified and validated biomarkers to test the ability of different feature selection algorithms to obtain the known result; the best algorithm may then be applicable to additional clinical studies.
"Many publications claim discoveries of biomarkers that don' t work in the clinic. "
Standardization
Another major challenge in biomarker identification, says Wang, has been the variations in microarray chips made by different manufacturers, as well as the differences in chips produced by the same manufacturer over time. "If the same patient sample is analyzed on two different chips, there will be variations. In biomarker validation this is a big issue," she notes. "Many publications claim discoveries of biomarkers that don't work in the clinic." "I used to be in industry," Wang says, "where it was important to have standardization of different platforms so they could talk to each other. Quality control (QC) and quality assurance (QA) are industry jobs, and something I pay attention to." Wang's caCORRECT improves the quality of collected microarray data by removing noise and artifacts (such as those produced by scratches, edge effects, and bubble effects) from the data, while retaining high-quality genes on the array. She notes that running QA on all microarray data is important before any biomarker selection. Once that has been done, Wang's omniBioMarker software can be used to identify and validate biomarkers from high-throughput gene expression datasets by searching healthy and cancer patient samples for genes most likely to be associated with cancer, as well as genes that appear to interact in cancer development. omniBioMarker also relates the selected biomarkers to clinical information. "The key focus for us is making it work for real medicine," Wang observes.
Future Directions
Wang's group currently has two more software tools under caBIG review-Q-IHC and omniVIsGrid-as well as others in development. Q-IHC analyzes and quantifies multi-spectral images, including quantum dot-stained histopathologic images, and onmiVisGrid is a grid-based tool that visualizes data and analysis processes of microarrays, biologic pathways, and clinical outcomes. "No matter what the data source is-genomics, proteomics, high-throughput, or next-generation sequencing-the goal is the same: QC, reproducibility, and reliability."
Wang's group is working closely with caBIG to develop common vocabulary guidelines and to draw input from the community. An algorithm developed in association with a wiki page can perform QC for users on their data, showing the results before and after quality correction and providing a quality score. With a wiki format, community users can annotate and comment on different chips and different manufacturers, enabling the user community to grow. In the future, Wang's plans include working with clinicians on biomarker validation and improving both reproducibility and reliability. "Challenges remain. One challenge is to develop and certify tools under caBIG. It's also a challenge to maintain software for many years. Obtaining sufficient funding is also challenging, as is maintenance of infrastructure. People like me are tool developers, the real users will be doctors and medical centers that will have to be willing to facilitate communication and share data. There are clinical cultural issues. These were discussed at the caBIG annual meeting. We've experienced cultural and sharing issues locally, but they are relatively easy to resolve. Eventually, we will accomplish our goal to improve translational research through validation," Wang concludes.
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